Combination of somatostatin analogues and dexamethasone (antisurvival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis
- 1 July 2007
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 100 (s2 Prostat) , 60-62
- https://doi.org/10.1111/j.1464-410x.2007.06958.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patientsJournal of Clinical Oncology, 2006
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone MetastasesClinical Cancer Research, 2004
- Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II studyUrology, 2004
- Mechanisms of Tumor Metastasis to the Bone: Challenges and OpportunitiesJournal of Bone and Mineral Research, 2003
- Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancerExpert Opinion on Investigational Drugs, 2001
- Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasionBritish Journal of Cancer, 2001
- Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate CancerMolecular Medicine, 2000